{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T02:18:42Z","timestamp":1787797122527,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,3,11]],"date-time":"2009-03-11T00:00:00Z","timestamp":1236729600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s00401-009-0513-4","type":"journal-article","created":{"date-parts":[[2009,3,10]],"date-time":"2009-03-10T10:37:12Z","timestamp":1236681432000},"page":"381-389","source":"Crossref","is-referenced-by-count":33,"title":["Receptor for advanced glycation end products is upregulated in optic neuropathy of Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"118","author":[{"given":"Michelle Y.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred N.","family":"Ross-Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Ying","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo A.","family":"Sadun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,3,11]]},"reference":[{"key":"513_CR1","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1038\/sj.emboj.7600415","volume":"23","author":"O Arancio","year":"2004","unstructured":"Arancio O, Zhang HP, Chen X et al (2004) RAGE potentiates abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23:4096\u20134105. doi: 10.1038\/sj.emboj.7600415","journal-title":"EMBO J"},{"key":"513_CR2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/s00109-005-0688-7","volume":"83","author":"A Bierhaus","year":"2005","unstructured":"Bierhaus A, Humpert PM, Morcos M et al (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876\u2013886. doi: 10.1007\/s00109-005-0688-7","journal-title":"J Mol Med"},{"key":"513_CR3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","volume":"112","author":"H Braak","year":"2006","unstructured":"Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389\u2013404. doi: 10.1007\/s00401-006-0127-z","journal-title":"Acta Neuropathol"},{"key":"513_CR4","first-page":"1699","volume":"143","author":"J Brett","year":"1993","unstructured":"Brett J, Schmidt AM, Yan SD et al (1993) Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143:1699\u20131712","journal-title":"Am J Pathol"},{"key":"513_CR5","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00018-002-8491-x","volume":"59","author":"LG Bucciarelli","year":"2002","unstructured":"Bucciarelli LG, Wendt T, Rong L et al (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117\u20131128. doi: 10.1007\/s00018-002-8491-x","journal-title":"Cell Mol Life Sci"},{"key":"513_CR6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/nm890","volume":"9","author":"R Deane","year":"2003","unstructured":"Deane R, Du Yan S, Submamaryan RK et al (2003) RAGE mediates amyloid-beta peptide transport across the blood\u2013brain barrier and accumulation in brain. Nat Med 9:907\u2013913. doi: 10.1038\/nm890","journal-title":"Nat Med"},{"key":"513_CR7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00401-006-0115-3","volume":"112","author":"JE Donahue","year":"2006","unstructured":"Donahue JE, Flaherty SL, Johanson CE et al (2006) RAGE, LRP-1, and amyloid-beta protein in Alzheimer\u2019s disease. Acta Neuropathol 112:405\u2013415. doi: 10.1007\/s00401-006-0115-3","journal-title":"Acta Neuropathol"},{"key":"513_CR8","first-page":"86","volume":"132","author":"DW Dickson","year":"1988","unstructured":"Dickson DW, Farlo J, Davies P, Crystal H, Fuld P, Yen SH (1988) Alzheimer\u2019s disease. A double-labeling immunohistochemical study of senile plaques. Am J Pathol 132:86\u2013101","journal-title":"Am J Pathol"},{"key":"513_CR9","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1212\/WNL.30.7.778","volume":"30","author":"PE Duffy","year":"1980","unstructured":"Duffy PE, Rapport M, Graf L (1980) Glial fibrillary acidic protein and Alzheimer-type senile dementia. Neurology 30:778\u2013782","journal-title":"Neurology"},{"key":"513_CR10","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1001\/archneur.62.11.1734","volume":"62","author":"E Emanuele","year":"2005","unstructured":"Emanuele E, D\u2019Angelo A, Tomaino C et al (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62:1734\u20131736. doi: 10.1001\/archneur.62.11.1734","journal-title":"Arch Neurol"},{"key":"513_CR11","first-page":"1347","volume-title":"Robbins and Cotran pathologic basis of disease","author":"MP Frosch","year":"2005","unstructured":"Frosch MP, Anthony DC, de Girolami U (2005) The central nervous system. In: Kumar V, Abbas AK, Fausto N (eds) Robbins and Cotran pathologic basis of disease, 7th edn. Elsevier Saunders, Philadelphia, pp 1347\u20131420","edition":"7"},{"key":"513_CR12","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1073\/pnas.86.19.7611","volume":"86","author":"WS Griffin","year":"1989","unstructured":"Griffin WS, Stanley LC, Ling C et al (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86:7611\u20137615. doi: 10.1073\/pnas.86.19.7611","journal-title":"Proc Natl Acad Sci USA"},{"key":"513_CR13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1001\/archneur.60.8.1119","volume":"60","author":"LE Hebert","year":"2003","unstructured":"Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60:1119\u20131122. doi: 10.1001\/archneur.60.8.1119","journal-title":"Arch Neurol"},{"key":"513_CR14","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM198608213150804","volume":"315","author":"DR Hinton","year":"1986","unstructured":"Hinton DR, Sadun AA, Blanks JC, Miller CA (1986) Optic-nerve degeneration in Alzheimer\u2019s disease. N Engl J Med 315:485\u2013487","journal-title":"N Engl J Med"},{"key":"513_CR15","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005072-199710000-00002","volume":"56","author":"BT Hyman","year":"1997","unstructured":"Hyman BT, Trojanowski JQ (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 56:1095\u20131097. doi: 10.1097\/00005072-199710000-00002","journal-title":"J Neuropathol Exp Neurol"},{"key":"513_CR16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0039-6257(89)90127-6","volume":"34","author":"B Katz","year":"1989","unstructured":"Katz B, Rimmer S (1989) Ophthalmologic manifestations of Alzheimer\u2019s disease. Surv Ophthalmol 34:31\u201343. doi: 10.1016\/0039-6257(89)90127-6","journal-title":"Surv Ophthalmol"},{"key":"513_CR17","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF03401729","volume":"4","author":"JJ Li","year":"1998","unstructured":"Li JJ, Dickson D, Hof PR, Vlassara H (1998) Receptors for advanced glycosylation endproducts in human brain: role in brain homeostasis. Mol Med 4:46\u201360","journal-title":"Mol Med"},{"key":"513_CR18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.brainres.2004.05.052","volume":"1018","author":"L Ma","year":"2004","unstructured":"Ma L, Nicholson LF (2004) Expression of the receptor for advanced glycation end products in Huntington\u2019s disease caudate nucleus. Brain Res 1018:10\u201317. doi: 10.1016\/j.brainres.2004.05.052","journal-title":"Brain Res"},{"key":"513_CR19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1172\/JCI2029","volume":"102","author":"JB Mackic","year":"1998","unstructured":"Mackic JB, Stins M, McComb JG et al (1998) Human blood-brain barrier receptors for Alzheimer\u2019s amyloid-beta 1\u201340. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 102:734\u2013743. doi: 10.1172\/JCI2029","journal-title":"J Clin Invest"},{"key":"513_CR20","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1212\/WNL.40.4.635","volume":"40","author":"TI Mandybur","year":"1990","unstructured":"Mandybur TI, Chuirazzi CC (1990) Astrocytes and the plaques of Alzheimer\u2019s disease. Neurology 40:635\u2013639","journal-title":"Neurology"},{"key":"513_CR21","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.brainres.2008.06.124","volume":"1230","author":"MC Miller","year":"2008","unstructured":"Miller MC, Tavares R, Johanson CE et al (2008) Hippocampal RAGE immunoreactivity in early and advanced Alzheimer\u2019s disease. Brain Res 1230:273\u2013280. doi: 10.1016\/j.brainres.2008.06.124","journal-title":"Brain Res"},{"key":"513_CR22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1212\/WNL.41.4.479","volume":"41","author":"SS Mirra","year":"1991","unstructured":"Mirra SS, Heyman A, McKeel D et al (1991) The Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer\u2019s disease. Neurology 41:479\u2013486","journal-title":"Neurology"},{"key":"513_CR23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.neurobiolaging.2003.11.001","volume":"25","author":"S Mruthinti","year":"2004","unstructured":"Mruthinti S, Buccafusco JJ, Hill WD et al (2004) Autoimmunity in Alzheimer\u2019s disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 25:1023\u20131032. doi: 10.1016\/j.neurobiolaging.2003.11.001","journal-title":"Neurobiol Aging"},{"key":"513_CR24","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.mcn.2005.02.012","volume":"29","author":"IG Onyango","year":"2005","unstructured":"Onyango IG, Tuttle JB, Bennett JP Jr (2005) Altered intracellular signaling and reduced viability of Alzheimer\u2019s disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol Cell Neurosci 29:333\u2013343. doi: 10.1016\/j.mcn.2005.02.012","journal-title":"Mol Cell Neurosci"},{"key":"513_CR25","doi-asserted-by":"crossref","first-page":"36330","DOI":"10.1074\/jbc.M706407200","volume":"282","author":"P Pichiule","year":"2007","unstructured":"Pichiule P, Chavez JC, Schmidt AM, Vannucci SJ (2007) Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia\/ischemia. J Biol Chem 282:36330\u201336340. doi: 10.1074\/jbc.M706407200","journal-title":"J Biol Chem"},{"key":"513_CR26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0306-4522(94)90547-9","volume":"63","author":"CJ Pike","year":"1994","unstructured":"Pike CJ, Cummings BJ, Monzavi R, Cotman CW (1994) Beta-amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer\u2019s disease. Neuroscience 63:517\u2013531. doi: 10.1016\/0306-4522(94)90547-9","journal-title":"Neuroscience"},{"key":"513_CR27","doi-asserted-by":"crossref","first-page":"16R","DOI":"10.1093\/glycob\/cwi053","volume":"15","author":"R Ramasamy","year":"2005","unstructured":"Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM (2005) Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15:16R\u201328R. doi: 10.1093\/glycob\/cwi053","journal-title":"Glycobiology"},{"key":"513_CR28","first-page":"64","volume":"12","author":"AA Sadun","year":"1989","unstructured":"Sadun AA (1989) The optic neuropathy of Alzheimer\u2019s disease. Metab Pediatr Syst Ophthalmol 12:64\u201368","journal-title":"Metab Pediatr Syst Ophthalmol"},{"key":"513_CR29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/0002-9394(87)90001-8","volume":"104","author":"AA Sadun","year":"1987","unstructured":"Sadun AA, Borchert M, DeVita E, Hinton DR, Bassi CJ (1987) Assessment of visual impairment in patients with Alzheimer\u2019s disease. Am J Ophthalmol 104:113\u2013120","journal-title":"Am J Ophthalmol"},{"key":"513_CR30","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0161-6420(90)32621-0","volume":"97","author":"AA Sadun","year":"1990","unstructured":"Sadun AA, Bassi CJ (1990) Optic nerve damage in Alzheimer\u2019s disease. Ophthalmology 97:9\u201317","journal-title":"Ophthalmology"},{"key":"513_CR31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0006-8993(00)03075-4","volume":"888","author":"N Sasaki","year":"2001","unstructured":"Sasaki N, Toki S, Chowei H et al (2001) Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer\u2019s disease. Brain Res 888:256\u2013262. doi: 10.1016\/S0006-8993(00)03075-4","journal-title":"Brain Res"},{"key":"513_CR32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0167-4889(00)00087-2","volume":"1498","author":"AM Schmidt","year":"2000","unstructured":"Schmidt AM, Yan SD, Yan SF, Stern DM (2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498:99\u2013111. doi: 10.1016\/S0167-4889(00)00087-2","journal-title":"Biochim Biophys Acta"},{"key":"513_CR33","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI200114002","volume":"108","author":"AM Schmidt","year":"2001","unstructured":"Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949\u2013955","journal-title":"J Clin Invest"},{"key":"513_CR34","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/S0169-409X(02)00160-6","volume":"54","author":"D Stern","year":"2002","unstructured":"Stern D, Yan SD, Yan SF, Schmidt AM (2002) Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 54:1615\u20131625. doi: 10.1016\/S0169-409X(02)00160-6","journal-title":"Adv Drug Deliv Rev"},{"key":"513_CR35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nm838","volume":"9","author":"T Wyss-Coray","year":"2003","unstructured":"Wyss-Coray T, Loike JD, Brionne TC et al (2003) Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 9:453\u2013457. doi: 10.1038\/nm838","journal-title":"Nat Med"},{"key":"513_CR36","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/382685a0","volume":"382","author":"SD Yan","year":"1996","unstructured":"Yan SD, Chen X, Fu J et al (1996) RAGE and amyloid-\u03b2 peptide neurotoxicity in Alzheimer\u2019s disease. Nature 382:685\u2013691. doi: 10.1038\/382685a0","journal-title":"Nature"},{"key":"513_CR37","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1471-4159.2004.02385.x","volume":"89","author":"BV Zlokovic","year":"2004","unstructured":"Zlokovic BV (2004) Clearing amyloid through the blood\u2013brain barrier. J Neurochem 89:807\u2013811. doi: 10.1111\/j.1471-4159.2004.02385.x","journal-title":"J Neurochem"},{"key":"513_CR38","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.tins.2005.02.001","volume":"28","author":"BV Zlokovic","year":"2005","unstructured":"Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer\u2019s neurodegeneration. Trends Neurosci 28:202\u2013208. doi: 10.1016\/j.tins.2005.02.001","journal-title":"Trends Neurosci"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-009-0513-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-009-0513-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-009-0513-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T17:23:21Z","timestamp":1559064201000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-009-0513-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,11]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1007\/s00401-009-0513-4","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,11]]}}}